Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank Pharmaceuticals Update  (Replay)
    Thursday, December 26, 2019 8:30 am EST
Toggle Summary Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
HOPKINTON, Mass. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore
Toggle Summary Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results
HOPKINTON, Mass. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the fourth
Toggle Summary Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCs Adjusting cost structure to fund operations into late 2022 HOPKINTON, Mass. , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc.
Toggle Summary Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program
HOPKINTON, Mass. , Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that the company has
Toggle Summary Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
HOPKINTON, Mass. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced two hepatitis B virus
Toggle Summary Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285
HOPKINTON, Mass. , Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has initiated
Toggle Summary Spring Bank Announces Investor Conference Presentations for the Remainder of 2019
HOPKINTON, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll ,
Toggle Summary Spring Bank Pharmaceuticals Reports Third Quarter 2019 Financial and Operational Results and Provides Corporate Update
Company to host conference call on Monday, November 11, 2019 at 4:30pm EST to discuss current HBV landscape and update on the company’s development programs HOPKINTON, Mass. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical
Toggle Summary Spring Bank Announces Interim Top-Line Results from the First Cohort of the Phase 2 Trial Evaluating Low-Dose Inarigivir Plus Vemlidy® in Chronic Hepatitis B Patients
7 of 30 patients were HBsAg responders with ≥ 0.5log₁₀ reduction Inarigivir 50mg plus Vemlidy® 25mg was generally safe and well tolerated at 12 weeks Evaluation of inarigivir 200mg and 400mg co-administered with Vemlidy is ongoing HOPKINTON, Mass. , Oct.
Toggle Summary Spring Bank to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York, NY
HOPKINTON, Mass. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin Driscoll ,